Trade Tensions Weigh Heavily on 10 Stocks

7. Recursion Pharmaceuticals Inc. (NASDAQ:RXRX)

Recursion Pharmaceuticals declined by 12.25 percent on Monday to close at $6.59 each as investor sentiment was dampened by disappointing earnings results for 2024.

In a statement on Friday, RXRX said it nearly doubled its net loss in the last quarter of 2024 at $179 million from $93 million in the same period a year earlier, as revenues halved to $4.5 million from $10.89 million year-on-year due to the timing of projects from the company’s Roche and Genentech collaboration.

Net loss in full-year 2024 also widened by 41 percent to $463.66 million from $328.07 million despite posting a 32-percent higher revenue at $58.8 million versus $44.58 million year-on-year due to revenue recognized from its Roche and Genentech collaboration related to the completion of its first neuroscience phenomap optioned by Roche and Genentech for $30 million.